French Immunotherapy Leader To Be Born From OSE Pharma-Effimune Merger
This article was originally published in Scrip
You may also be interested in...
French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist in ulcerative colitis.
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.